Cited by 229Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorReceptor Mechanisms and Signaling

The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

Open access

Seeman, Philip·2011·CNS Neuroscience & Therapeutics

DOI 10.1111/j.1755-5949.2010.00162.xPMC PMC6493870

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The dopamine D2 receptor is the common target for antipsychotics, and the antipsychotic clinical doses correlate with their affinities for this receptor. Antipsychotics quickly enter the brain to occupy 60-80% of brain D2 receptors in patients (the agonist aripiprazole occupies up to 90%), with most clinical improvement occurring within a few days. The D2 receptor can exist in a state of high-affinity (D2(High) ) or in a state of low-affinity for dopamine (D2Low). AIM: The present aim is to review why individuals with schizophrenia are generally supersensitive to dopamine-like drugs such as amphetamine or methyphenidate, and whether the D2(High) state is a common basis for dopamine supersensitivity in the animal models of schizophrenia. RESULTS: All animal models of schizophrenia reveal elevations in D2(High) receptors. These models include brain lesions, sensitization by drugs (amphetamine, phencyclidine, cocaine, corticosterone), birth injury, social isolation, and gene deletions in pathways for NMDA, dopamine, GABA, acetylcholine, and norepinephrine. CONCLUSIONS: These multiple abnormal pathways converge to a final common pathway of dopamine supersensitivity and elevated D2(High) receptors, presumably responsible for psychotic symptoms. Although antipsychotics alleviate psychosis and reverse the elevation of D2(High) receptors, long-term antipsychotics can further enhance dopamine supersensitivity in patients. Therefore, switching from a traditional antipsychotic to an agonist antipsychotic (aripiprazole) can result in psychotic signs and symptoms. Clozapine and quetiapine do not elicit parkinsonism or tardive dyskinesia because they are released from D2 within 12 to 24 h. Traditional antipsychotics remain attached to D2 receptors for days, preventing relapse, but allowing accumulation that can lead to tardive dyskinesia. Future goals include imaging D2(High) receptors and desensitizing them in early-stage psychosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1755-5949.2010.00162.x

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multiple receptors for dopamine
Kebabian, J. W., & Calne, D. B. (1979) · Nature · doi:10.1038/277093a0 · Cited by 3,756
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Self-citation
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citation
Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,420
Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citation
Cloning and expression of a rat D2 dopamine receptor cDNA
Bunzow, J. R., Tol, H. H. M. V., Grandy, D. K., Albert, P. R., Salon, J. A., Christie, M. J., Machida, C. A., Neve, K. A., & Civelli, O. (1988) · Nature · doi:10.1038/336783a0 · Cited by 1,116
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
Allen, N. C., Bagade, S., McQueen, M. B., Ioannidis, J. P. A., Kavvoura, F. K., Khoury, M. J., Tanzi, R. E., & Bertram, L. (2008) · Nature Genetics · doi:10.1038/ng.171 · Cited by 1,054
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Self-citation

Show all 104 references

Research works printed but not linked: 3

Van Rossum, 1967, Neuro-Psycho-Pharmacology, Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-Psycho-pharmacologicum, 321
Seeman, 1974, Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers, Fed Proc, 33, 246
Seeman, 2009, Psychosis: Discovery of the antipsychotic receptor, 148

Sorted by citations

The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies
Howes, O. D., Kambeitz, J., Kim, E., Stahl, D., Slifstein, M., Abi-Dargham, A., & Kapur, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2012.169 · Cited by 967
The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue
Brisch, R., Saniotis, A., Wolf, R. J., Bielau, H., Bernstein, H., Steiner, J. H., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 575
The effects of social isolation stress and discrimination on mental health
Brandt, L., Liu, S., Heim, C. C., & Heinz, A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02178-4 · Cited by 549
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Does tobacco use cause psychosis? Systematic review and meta-analysis
Gurillo, P., Jauhar, S., Murray, R. M., & MacCabe, J. H. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00152-2 · Cited by 300
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Amphetamine-induced psychosis - a separate diagnostic entity or primary psychosis triggered in the vulnerable?
Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E., Medhus, S., Tanum, L., & Franck, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-221 · Cited by 244
A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings
Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A. S., Udawela, M., & Dean, B. (2015) · International Journal of Endocrinology · doi:10.1155/2015/615356 · Cited by 245
Improving target assessment in biomedical research: the GOT-IT recommendations
Emmerich, C. H., Martinez‐Gamboa, L., Hofmann, M. C. J., Bonin, M., Arbach, O., Schendel, P., Gerlach, B., Hempel, K., Bespalov, A., Dirnagl, U., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0087-3 · Cited by 243
Schizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: From the elephant to the mouse
Keshavan, M. S., Nasrallah, H. A., & Tandon, R. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.011 · Cited by 233
Cognitive Behavioral Therapy for Subjects at Ultrahigh Risk for Developing Psychosis: A Randomized Controlled Clinical Trial
van der Gaag, M., Nieman, D. H., Rietdijk, J., Dragt, S., Ising, H. K., Klaassen, R. M. C., Koeter, M., Cuijpers, P., Wunderink, L., & Linszen, D. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs105 · Cited by 209
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
Seeman, P. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.195 · Cited by 189
Self-citation
Imaging of Thalamocortical Dysrhythmia in Neuropsychiatry
Schulman, J. J., Cancro, R., Lowe, S., Lu, F., Walton, K. D., & Llinás, R. R. (2011) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2011.00069 · Cited by 167
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors
Seeman, P. M. (2015) · Synapse · doi:10.1002/syn.21805 · Cited by 160
Self-citation
Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data
Sakurai, H., Bies, R. R., Stroup, T. S., Keefe, R. S. E., Rajji, T. K., Suzuki, T., Mamo, D. C., Pollock, B. G., Watanabe, K., Mimura, M., et al. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr189 · Cited by 148
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications
Pei, Y., Asif-Malik, A., & Canales, J. J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00148 · Cited by 134
An update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135
Clozapine, a Fast-Off-D2 Antipsychotic
Seeman, P. M. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400189s · Cited by 129
Self-citation
Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management
Chang, A., & Fox, S. H. (2016) · Drugs · doi:10.1007/s40265-016-0600-5 · Cited by 133
Recent advances in the search for D3- and D4-selective drugs: probes, models and candidates
Löber, S., Hübner, H., Tschammer, N., & Gmeiner, P. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.003 · Cited by 109
Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis
Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., & Hashimoto, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828ea95c · Cited by 98
Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review
Yin, J., Barr, A. M., Ramos‐Miguel, A., & Procyshyn, R. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160606093602 · Cited by 99
Alzheimer's disease: β‐amyloid plaque formation in human brain
Seeman, P. M., & Seeman, N. (2011) · Synapse · doi:10.1002/syn.20957 · Cited by 103
Self-citation
Dystonia and dopamine: From phenomenology to pathophysiology
Ribot, B., Aupy, J., Vidailhet, M., Mazère, J., Pisani, A., Bézard, E., Guehl, D., & Burbaud, P. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101678 · Cited by 96
Clozapine's Multiple Cellular Mechanisms: What Do We Know after More than Fifty Years? a Systematic Review and Critical Assessment of Translational Mechanisms Relevant for Innovative Strategies in Treatment-Resistant Schizophrenia
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 96
Anaesthesia for positron emission tomography scanning of animal brains
Alstrup, A. K. O., & Smith, D. F. (2013) · Laboratory Animals · doi:10.1258/la.2012.011173 · Cited by 89
Is schizophrenia a dopamine supersensitivity psychotic reaction?
Seeman, M. V., & Seeman, P. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.003 · Cited by 87
Self-citation
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Vauquelin, G., Bostoen, S., Vanderheyden, P., & Seeman, P. M. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-012-0734-2 · Cited by 80
Self-citation
Dopamine, fronto-striato-thalamic circuits and risk for psychosis.
Dandash, O., Pantelis, C., & Fornito, A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.08.020 · Cited by 89
Current Concepts on the Physiopathological Relevance of Dopaminergic Receptors
Ledonne, A., & Mercuri, N. B. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00027 · Cited by 86
The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 81
Animal Models of Psychosis: Current State and Future Directions
Forrest, A. D., Coto, C. A., & Siegel, S. J. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0013-2 · Cited by 69
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
Clark, S. D., & Abi‐Dargham, A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.012 · Cited by 68
The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course
Kuepper, R., Skinbjerg, M., & Abi‐Dargham, A. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_1 · Cited by 65
Imaging Agonist-Induced D2/D3 Receptor Desensitization and Internalization In Vivo with PET/fMRI
Sander, C. Y. M., Hooker, J. M., Catana, C., Rosen, B. R., & Mandeville, J. B. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.296 · Cited by 66
History of the dopamine hypothesis of antipsychotic action
Seeman, M. V. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.355 · Cited by 69
Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments
Bartzokis, G. (2011) · Frontiers in bioscience · doi:10.2741/3881 · Cited by 60
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications
Lian, J., Huang, X., Pai, N. B., & Deng, C. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.011 · Cited by 61
How gender affects the pharmacotherapeutic approach to treating psychosis – a systematic review
Lange, B., Mueller, J. K., Leweke, F. M., & Bumb, J. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1288722 · Cited by 60
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders
Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53
Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice
Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 52
Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of ‘schizophrenia-like’ behaviour in the rat
Gaskin, P. L. R., Alexander, S. P. H., & Fone, K. C. F. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3424-y · Cited by 57
Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in C. elegans
Masoudi, N., Ibanez-Cruceyra, P., Offenburger, S.-L., Holmes, A., & Gartner, A. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004767 · Cited by 48
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms
Li, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116654697 · Cited by 51
Excited Delirium and Sudden Death: A Syndromal Disorder at the Extreme End of the Neuropsychiatric Continuum
Mash, D. C. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00435 · Cited by 53
Doping the Mind
Ranganath, A., & Jacob, S. N. (2015) · The Neuroscientist · doi:10.1177/1073858415602850 · Cited by 52
Effect of C-Terminal S-Palmitoylation on D2 Dopamine Receptor Trafficking and Stability
Ebersole, B., Petko, J., Woll, M. P., Murakami, S., Sokolina, K., Wong, V., Štagljar, I., Lüscher, B., & Levenson, R. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140661 · Cited by 50
Mesolimbic dopamine dysregulation as a signature of information processing deficits imposed by prenatal THC exposure
Sagheddu, C., Traccis, F., Serra, V., Congiu, M., Frau, R., Cheer, J. F., & Melis, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110128 · Cited by 49
Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia
Valle-León, M., Callado, L. F., Aso, E., Cajiao-Manrique, M. D. M., Sahlholm, K., López‐Cano, M., Soler, C., Altafaj, X., Watanabe, M., Ferré, S., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00872-9 · Cited by 45
Effects on resting cerebral blood flow and functional connectivity induced by metoclopramide: a perfusion MRI study in healthy volunteers
Fernández‐Seara, M. A., Aznárez‐Sanado, M., Mengual, E., Irigoyen, J., Heukamp, F. H., & Pastor, M. A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01161.x · Cited by 46
Mutation of Semaphorin-6A Disrupts Limbic and Cortical Connectivity and Models Neurodevelopmental Psychopathology
Rünker, A. E., O’Tuathaigh, C. M. P., Dunleavy, M., Morris, D. W., Little, G. E., Corvin, A. P., Gill, M., Henshall, D. C., Waddington, J. L., & Mitchell, K. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026488 · Cited by 52
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer’s disease
Reeves, S., McLachlan, E., Bertrand, J., D’Antonio, F., Brownings, S., Nair, A., Greaves, S., Smith, A., Taylor, D. M., Dunn, J., et al. (2017) · Brain · doi:10.1093/brain/aww359 · Cited by 45
Making Sense of: Sensitization in Schizophrenia
Weidenauer, A., Bauer, M., Sauerzopf, U., Bartova, L., Praschak-rieder, N., Sitte, H., Kasper, S., & Willeit, M. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw081 · Cited by 44
The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor
Sahlholm, K., Zeberg, H., Nilsson, J., Ögren, S. O., Fuxé, K., & Århem, P. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.001 · Cited by 44
Mutation of Elfn1 in Mice Causes Seizures and Hyperactivity
Dolan, J., & Mitchell, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080491 · Cited by 45
Alterations of GABAergic and dopaminergic systems in mutant mice with disruption of exons 2 and 3 of the Disc1 gene
NAKAI, T., Nagai, T., Wang, R., Yamada, S., Kuroda, K., Kaibuchi, K., & Yamada, K. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.009 · Cited by 41
Are dopamine D2 receptors out of control in psychosis?
Seeman, P. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.07.006 · Cited by 42
Self-citation
Schizophrenia and Substance Abuse Comorbidity: Nicotine Addiction and the Neonatal Quinpirole Model
Brown, R. W., Maple, A. M., Perna, M. K., Sheppard, A. B., Cope, Z. A., & Kostrzewa, R. M. (2012) · Developmental Neuroscience · doi:10.1159/000338830 · Cited by 39
Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications
van Wieringen, J., Booij, J., Shalgunov, V., Elsinga, P., & Michel, M. (2012) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-012-0817-0 · Cited by 40
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38
Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Using Computational Modeling to Capture Schizophrenia-Specific Reinforcement Learning Differences and Their Implications on Patient Classification
Geana, A., Barch, D. M., Gold, J. M., Carter, C. S., MacDonald, A. W., Ragland, J. D., Silverstein, S. M., & Frank, M. J. (2021) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2021.03.017 · Cited by 45
Amphetamine Induced Striatal Dopamine Release Measured with an Agonist Radiotracer in Schizophrenia
Frankle, W., Paris, J., Himes, M. L., Mason, N. S., Mathis, C. A., & Narendran, R. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.032 · Cited by 32
A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia
Yee, B. K., & Singer, P. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1611-0 · Cited by 31
Could cannabidiol be used as an alternative to antipsychotics?
Fakhoury, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.013 · Cited by 33
Dopamine Receptor Homooligomers and Heterooligomers in Schizophrenia
Perreault, M. L., O’Dowd, B. F., & George, S. R. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00228.x · Cited by 34
Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density
Lian, J., Huang, X., Pai, N. B., & Deng, C. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.005 · Cited by 29
Striatal development involves a switch in gene expression networks, followed by a myelination event: Implications for neuropsychiatric disease
Novak, G., Fan, T., O’Dowd, B. F., & George, S. R. (2012) · Synapse · doi:10.1002/syn.21628 · Cited by 29
Adolescent nicotine sensitization and effects of nicotine on accumbal dopamine release in a rodent model of increased dopamine D2 receptor sensitivity
Perna, M. K., & Brown, R. W. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.037 · Cited by 28
Chronic Toxoplasma gondii in Nurr1-Null Heterozygous Mice Exacerbates Elevated Open Field Activity
Eells, J. B., Varela‐Stokes, A. S., Guo‐Ross, S. X., Kummari, E., Smith, H. M., Cox, E., & Lindsay, D. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119280 · Cited by 28
Synapsin II gene expression in the dorsolateral prefrontal cortex of brain specimens from patients with schizophrenia and bipolar disorder: effect of lifetime intake of antipsychotic drugs
Tan, M. L., Dyck, B. A., Gabriele, J. P., Daya, R. P., Thomas, N., Sookram, C. D., Basu, D., Ferro, M. A., Chong, V. Z., & Mishra, R. K. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.6 · Cited by 27
Pharmacokinetic–Pharmacodynamic Modeling of Severity Levels of Extrapyramidal Side Effects With Markov Elements
Reddy, V. P., Petersson, K., Suleiman, A., Vermeulen, A., Proost, J., & Friberg, L. E. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.9 · Cited by 26
Estrogen potentiates the behavioral and nucleus accumbens dopamine response to continuous haloperidol treatment in female rats
Madularu, D., Shams, W. M., & Brake, W. G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12401 · Cited by 25
Transient activation of dopaminergic neurons during development modulates visual responsiveness, locomotion and brain activity in a dopamine ontogeny model of schizophrenia
Calcagno, B., Eyles, D. W., van Alphen, B., & van Swinderen, B. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.139 · Cited by 24
Following the genes: a framework for animal modeling of psychiatric disorders
Mitchell, K. J., Huang, Z. J., Moghaddam, B., & Sawa, A. (2011) · BMC Biology · doi:10.1186/1741-7007-9-76 · Cited by 27
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
Crespo‐Facorro, B., Pelayo‐Terán, J. M., & Son, J. M.-V. (2016) · Neurology and Therapy · doi:10.1007/s40120-016-0050-8 · Cited by 27
Affinity States of Striatal Dopamine D2 Receptors in Antipsychotic-Free Patients with Schizophrenia
Kubota, M., Nagashima, T., Takano, H., Kodaka, F., Fujiwara, H., Takahata, K., Moriguchi, S., Kimura, Y., Higuchi, M., Okubo, Y., et al. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx063 · Cited by 25
Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
Tanaka, M., Kunugi, A., Suzuki, A., Suzuki, N., Suzuki, M., & Kimura, H. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.479 · Cited by 24
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances
Inoue, Y., Tsuchimori, K., & Nakamura, H. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.09.006 · Cited by 25
Differential effects of oxycodone, hydrocodone, and morphine on the responses of D2/D3 dopamine receptors
Emery, M. A., Bates, M. L. S., Wellman, P. J., & Eitan, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.023 · Cited by 24
Hunting for the high‐affinity state of G‐protein‐coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging
Shalgunov, V., van Waarde, A., Booij, J., Michel, M. C., Dierckx, R., & Elsinga, P. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21552 · Cited by 24
Analysis of the Glutamate Agonist LY404,039 Binding to Nonstatic Dopamine Receptor D2 Dimer Structures and Consensus Docking
Salmas, R. E., Seeman, P. M., Aksoydan, B., Erol, İ., Kantarcioglu, I., Stein, M., Yurtsever, M., & Durdağı, S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00070 · Cited by 24
Self-citation
Swan song for schizophrenia?
Henderson, S., & Malhi, G. S. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414529382 · Cited by 23
Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole
Koener, B., Focant, M. C., Bosier, B., Maloteaux, J., & Hermans, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.08.007 · Cited by 23
Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits
Brami‐Cherrier, K., Anzalone, A., Ramos, M., Forné, I., Macciardi, F. M., Imhof, A., & Borrelli, E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.67 · Cited by 22
What proportion of striatal D2 receptors are occupied by endogenous dopamine at baseline? A meta-analysis with implications for understanding antipsychotic occupancy
Caravaggio, F., Iwata, Y., Kim, J., Shah, P., Gerretsen, P., Remington, G. J., & Graff‐Guerrero, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.034 · Cited by 21
Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal
Iasevoli, F., Avagliano, C., D’Ambrosio, L., Barone, A., Ciccarelli, M., Simone, G. D., Mazza, B., Vellucci, L., & de Bartolomeis, A. (2023) · Biomedicines · doi:10.3390/biomedicines11030895 · Cited by 22
Aripiprazole, jeu pathologique et sexualité compulsive
Mété, D., Dafreville, C., Paitel, V., & Wind, P. (2016) · L Encéphale · doi:10.1016/j.encep.2016.01.003 · Cited by 21
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late‐onset schizophrenia‐like psychosis (VLOSLP)
Reeves, S., Eggleston, K., Cort, E., McLachlan, E., Brownings, S., Nair, A., Greaves, S., Smith, A., Dunn, J., Marsden, P. K., et al. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4758 · Cited by 20
Differential Effects of Oxycodone, Hydrocodone, and Morphine on Activation Levels of Signaling Molecules
Emery, M. A., Bates, M. L. S., Wellman, P. J., & Eitan, S. (2015) · Pain Medicine · doi:10.1111/pme.12918 · Cited by 20
LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment
Li, M.-L., Yang, S.-S., Xing, B., Ferguson, B. R., Gulchina, Y., Li, Y.-C., Li, F., Hu, X.-Q., & Gao, W. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.019 · Cited by 19
Age-dependent changes in cocaine sensitivity across early ontogeny in male and female rats: possible role of dorsal striatal D2High receptors
McDougall, S. A., Eaton, S. E., Mohd‐Yusof, A., & Crawford, C. A. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3860-3 · Cited by 20
Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity
Nani, J. V. S., Fonseca, M. D. C., Engi, S. A., Perillo, M. G., Dias, C. S. B., Gazarini, M. L., Korth, C., Cruz, F. C., & Hayashi, M. A. F. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119897562 · Cited by 20
Postnatal maternal deprivation and pubertal stress have additive effects on dopamine D2 receptor and CaMKII beta expression in the striatum
Novak, G., Fan, T., O’Dowd, B. F., & George, S. R. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.01.001 · Cited by 20
Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study
Suzuki, T., Graff‐Guerrero, A., Uchida, H., Remington, G. J., Caravaggio, F., Borlido, C., Pollock, B. G., Mulsant, B. H., Luca, V. D., Ismail, Z., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3012-1 · Cited by 20
Late-Life Effects of Chronic Methamphetamine Exposure during Puberty on Behaviour and Corticostriatal Mono-Amines in Social Isolation-Reared Rats
Strauss, L., Brink, C. B., Möller, M., Stein, D. J., & Harvey, B. H. (2014) · Developmental Neuroscience · doi:10.1159/000357495 · Cited by 18
A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia
Kim, Y., Choi, J., & Park, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040734 · Cited by 20
Dopamine D2 up-regulation in psychosis patients after antipsychotic drug treatment
Thompson, I. A., de Vries, E. F. J., & Sommer, I. E. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000598 · Cited by 19
The Unique Properties of the Prefrontal Cortex and Mental Illness
Gao, W., Wang, H.-X., Melissa, A., & Li, Y. (2012) · InTech eBooks · doi:10.5772/35868 · Cited by 17
G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis
Oda, Y., Tadokoro, S., Takase, M., Kanahara, N., Watanabe, H., Shirayama, Y., Hashimoto, K., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115593903 · Cited by 19

Authors: Seeman, P.
Affiliations: University of Toronto (CA)
Corresponding author: Seeman, Philip
ORCID: Seeman, Philip
Venue: CNS Neuroscience & Therapeutics
Publisher: Wiley
Published: 2011-03-15
Volume: 17
Issue: 2
Pages: 118-132
ISSN: 1755-5930 (ISSN-L)
DOI: 10.1111/j.1755-5949.2010.00162.x
PMC: PMC6493870
OpenAlex: W2113742168
Cited by: 228
References: 104
Citations by year: 2026: 11 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 16 · 2021: 12 · 2020: 17 · 2019: 9 · 2018: 9 · 2017: 18 · 2016: 23 · 2015: 22 · 2014: 16 · 2013: 23 · 2012: 21
FWCI: 13.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1631 d)
Locations: CNS Neuroscience & Therapeutics (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords: schizophrenia, dopamine D2 receptor, dopamine supersensitivity, animal models of schizophrenia, antipsychotic drugs, aripiprazole, tardive dyskinesia, parkinsonism, amphetamine sensitivity, phencyclidine, birth trauma, social isolation, gene deletion, NMDA receptor, GABA, acetylcholine, norepinephrine, receptor desensitization, psychosis
MeSH terms: Animals, Brain, Disease Models, Animal, Dopamine, Gene Expression Regulation, Humans, Schizophrenia, Antipsychotic Agents, Receptors, Dopamine D2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks